Study Design1,2
Study Population1,2
Premenopausal women 18–50 with surgically or directly visualised endometriosis with or without histological confirmation, or with histological diagnosis alone.
Co-Primary Endpoints1,2
Proportion of responders to Ryeqo based on the dysmenorrhoea and NMPP NRS scores
(24 weeks vs placebo in SPIRIT 1 and 2, 1 and 2 years in the long-term extension)
Key Secondary Endpoints1,2
- Pain (change in EHP-30 pain domain score)
- Dysmenorrhoea (change in average NRS score)
- NMPP (change in average NRS score)
- Overall pelvic pain (change in average NRS score)
- Dyspareunia (change in average NRS score)
- Proportion of patients not using opioids for endometriosis-associated pain
- Proportion of patients not using analgesics for endometriosis-associated pain (SPIRIT 1 and the long-term extension) or change from baseline in analgesic use (based on average daily pill count; SPIRIT 2)
For more information on the SPIRIT studies please see the full publication:
You are now leaving the Ryeqo Australia website
You have selected a link that will take you to a site maintained by a third party who is solely responsible for its contents. The information you are about to be referred to may not comply with the Australian regulatory environment and you should refer to the Consumer Medicine Information for products to fully understand the terms of a product's registration in Australia; the intent of providing this material is informational and not as advice. Gedeon Richter provides this link as a service to website visitors. Gedeon Richter is not responsible for the privacy policy of any third party websites.
Click ‘cancel’ to return to Ryeqo Australia site or ‘continue’ to proceed.
You are now leaving the Ryeqo Australia website
You have selected a link that will take you to a site maintained by a third party who is solely responsible for its contents. The information you are about to be referred to may not comply with the Australian regulatory environment and you should refer to the Consumer Medicine Information for products to fully understand the terms of a product's registration in Australia; the intent of providing this material is informational and not as advice. Gedeon Richter provides this link as a service to website visitors. Gedeon Richter is not responsible for the privacy policy of any third party websites.
Click ‘cancel’ to return to Ryeqo Australia site or ‘continue’ to proceed.
*Ryeqo contains 40 mg relugolix, 1 mg estradiol and 0.5 mg norethisterone acetate.3
Abbreviations: EHP-30, Endometriosis Health Profile-30; NMPP, non-menstrual pelvic pain; NRS, Numerical Rating Scale.
References
- Giudice LC et al. Lancet. 2022;399:2267–2279.
- Becker CM et al. Hum Reprod 2024;39(3):526–537.
- Ryeqo Approved Product Information. January 2024.